Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 175-182

  Mpakou, Vassiliki E ^a   Kontsioti, Frieda ^a   Papageorgiou, Sotiris ^a   Spathis, Aris ^a   Kottaridi, Christine ^a   Girkas, Kostas ^a   Karakitsos, Petros ^a   Dimitriadis, George ^a   Dervenoulas, Ioannis ^a   Pappa, Vasiliki ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute myeloid leukemia; Apoptosis; C kit; Dasatinib; Kasumi 1; VEGF VEGFR 2 pathway

Indexed keywords

CASPASE 3; DASATINIB; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL PROLIFERATION; CHROMOSOME 22Q; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; ENZYME ACTIVATION; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES; TRANSLOCATION, GENETIC;

EID: 84872370267     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.011     Document Type: Article

References (50)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Kelly L.M., Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002, 3:179-198.
3. Schnittger S., Kohl T.M., Haferlach T., Kern W., Hiddemann W., Spiekermann K., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107:1791-1799.
4. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
5. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003, 121:775-777.
6. Bloomfield C.D., Shuma C., Regal L., Philip P.P., Hossfeld D.K., Hagemeijer A.M., et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the fourth international workshop on chromosomes in leukemia. Cancer 1997, 80:2191-2198.
7. Mrozek K., Prior T.W., Edwards C., Marcucci G., Carroll A.J., Snyder P.J., et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2001, 19:2482-2492.
8. Ferrao P., Gonda T.J., Ashman L.K. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood 1997, 90:4539-4552.
9. Paschka P., Marcucci G., Ruppert A.S., Mrozek K., Chen H., Kittles R.A., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911.
10. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005, 102:3395-3400.
11. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
12. O'Hare T., Walters D.K., Stoffregen E.P., Sherbenou D.W., Heinrich M.C., Deininger M.W., et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005, 11:6987-6993.
13. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
14. Guilhot F., Apperley J., Kim D.W., Bullorsky E.O., Baccarani M., Roboz G.J., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007, 109:4143-4150.
15. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108:286-291.
16. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
17. Gambacorti-Passerini C., Gasser M., Ahmed S., Assouline S., Scapozza L. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 2005, 19:1267-1269.
18. Van Etten R.A. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004, 28(Suppl. 1):S21-S28.
19. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
20. Economopoulou P., Pappa V., Kontsioti F., Papageorgiou S., Foukas P., Liakata E., et al. Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. Ann Hematol 2010, 89:233-239.
21. Guerrouahen B.S., Futami M., Vaklavas C., Kanerva J., Whichard Z.L., Nwawka K., et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010, 16:1149-1158.
22. Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008, 68:9624-9633.
23. Redner R.L., Wang J., Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999, 94:417-428.
24. Nam S., Williams A., Vultur A., List A., Bhalla K., Smith D., et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007, 6:1400-1405.
25. Nguyen T.K., Rahmani M., Harada H., Dent P., Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007, 109:4006-4015.
26. Nunoda K., Tauchi T., Takaku T., Okabe S., Akahane D., Sashida G., et al. Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 2007, 26:4179-4188.
27. Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991, 77:2031-2036.
28. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993, 12:2715-2721.
29. Okuda T., Cai Z., Yang S., Lenny N., Lyu C.J., van Deursen J.M., et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998, 91:3134-3143.
30. Yergeau D.A., Hetherington C.J., Wang Q., Zhang P., Sharpe A.H., Binder M., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997, 15:303-306.
31. Serve H., Yee N.S., Stella G., Sepp-Lorenzino L., Tan J.C., Besmer P. Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J 1995, 14:473-483.
32. Cairoli R., Beghini A., Grillo G., Nadali G., Elice F., Ripamonti C.B., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
33. Ozawa Y., Williams A.H., Estes M.L., Matsushita N., Boschelli F., Jove R., et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 2008, 32:893-903.
34. Finn R.S., Dering J., Ginther C., Wilson C.A., Glaspy P., Tchekmedyian N., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/" triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326.
35. Johnson F.M., Saigal B., Talpaz M., Donato N.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005, 11:6924-6932.
36. Shor A.C., Keschman E.A., Lee F.Y., Muro-Cacho C., Letson G.D., Trent J.C., et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007, 67:2800-2808.
37. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
38. Nam S., Kim D., Cheng J.Q., Zhang S., Lee J.H., Buettner R., et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189.
39. Schittenhelm M.M., Shiraga S., Schroeder A., Corbin A.S., Griffith D., Lee F.Y., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
40. Han L., Schuringa J.J., Mulder A., Vellenga E. Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases. Ann Hematol 2010, 89:861-871.
41. Larizza L., Magnani I., Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005, 46:247-255.
42. Imai N., Shikami M., Miwa H., Suganuma K., Hiramatsu A., Watarai M., et al. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol 2006, 135:673-682.
43. Spiekermann K., Faber F., Voswinckel R., Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 2002, 30:767-773.
44. List A.F., Glinsmann-Gibson B., Stadheim C., Meuillet E.J., Bellamy W., Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 2004, 32:526-535.
45. Bromann P.A., Korkaya H., Courtneidge S.A. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004, 23:7957-7968.
46. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006, 8:1223-1234.
47. Gavard J., Patel V., Gutkind J.S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 2008, 14:25-36.
48. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375:577-581.
49. Kolb E.A., Gorlick R., Houghton P.J., Morton C.L., Lock R.B., Tajbakhsh M., et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1198-1206.
50. Fabarius A., Giehl M., Rebacz B., Kramer A., Frank O., Haferlach C., et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 2008, 93:1145-1154.